APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Prophylactic Human Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Prophylactic Human Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174029080426 December 2025197 pages

Choose your research edition.

Industry ResearchProphylactic Human Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Prophylactic Human Vaccine Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Prophylactic Human Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prophylactic Human Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Prophylactic Human Vaccine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Prophylactic Human Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Prophylactic Human Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Prophylactic Human Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prophylactic Human Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Prophylactic Human Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Prophylactic Human Vaccine market include GSK, Sanofi, Merck, Zoetis, Merial, McKesson Medical and Biovac, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Prophylactic Human Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prophylactic Human Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prophylactic Human Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prophylactic Human Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Prophylactic Human Vaccine Segment by Company

GSK

Sanofi

Merck

Zoetis

Merial

McKesson Medical

Biovac

Prophylactic Human Vaccine Segment by Type

Inactivated Vaccine

Attenuated Vaccine

Others

Prophylactic Human Vaccine Segment by Application

Hospital

Scientific Research

Others

Prophylactic Human Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Prophylactic Human Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Prophylactic Human Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Prophylactic Human Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Prophylactic Human Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prophylactic Human Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prophylactic Human Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prophylactic Human Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Prophylactic Human Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prophylactic Human Vaccine industry.

Chapter 3: Detailed analysis of Prophylactic Human Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Prophylactic Human Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Prophylactic Human Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Prophylactic Human Vaccine Industry Trends Table 2. Prophylactic Human Vaccine Industry Drivers Table 3. Prophylactic Human Vaccine Industry Opportunities and Challenges Table 4. Prophylactic Human Vaccine Industry Restraints Table 5. Global Prophylactic Human Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Prophylactic Human Vaccine Revenue Share by Company (2021-2026) Table 7. Global Prophylactic Human Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Prophylactic Human Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Prophylactic Human Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Prophylactic Human Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Prophylactic Human Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Prophylactic Human Vaccine Company, Product Type & Application Table 13. Global Prophylactic Human Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Prophylactic Human Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Inactivated Vaccine Table 18. Significant Companies of Attenuated Vaccine Table 19. Significant Companies of Others Table 20. Global Prophylactic Human Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Prophylactic Human Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Prophylactic Human Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Prophylactic Human Vaccine Sales Volume Share by Type (2021-2026) Table 24. Global Prophylactic Human Vaccine Sales Volume Share by Type (2027-2032) Table 25. Global Prophylactic Human Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Prophylactic Human Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Prophylactic Human Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Prophylactic Human Vaccine Sales Value Share by Type (2021-2026) Table 29. Global Prophylactic Human Vaccine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Scientific Research Table 32. Significant Companies of Others Table 33. Global Prophylactic Human Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Prophylactic Human Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Prophylactic Human Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Prophylactic Human Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Prophylactic Human Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Prophylactic Human Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Prophylactic Human Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Prophylactic Human Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Prophylactic Human Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Prophylactic Human Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Prophylactic Human Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Prophylactic Human Vaccine Sales by Region (2021-2026) & (K Units) Table 45. Global Prophylactic Human Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Prophylactic Human Vaccine Sales by Region (2027-2032) & (K Units) Table 47. Global Prophylactic Human Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Prophylactic Human Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Prophylactic Human Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Prophylactic Human Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Prophylactic Human Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Prophylactic Human Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Prophylactic Human Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Prophylactic Human Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Prophylactic Human Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Prophylactic Human Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Prophylactic Human Vaccine Sales by Country (2021-2026) & (K Units) Table 58. Global Prophylactic Human Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Prophylactic Human Vaccine Sales by Country (2027-2032) & (K Units) Table 60. Global Prophylactic Human Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Prophylactic Human Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Prophylactic Human Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Prophylactic Human Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Prophylactic Human Vaccine Sales Value Market Share by Country (2027-2032) Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. GSK Prophylactic Human Vaccine Product Portfolio Table 69. GSK Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Sanofi Prophylactic Human Vaccine Product Portfolio Table 74. Sanofi Recent Development Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck Prophylactic Human Vaccine Product Portfolio Table 79. Merck Recent Development Table 80. Zoetis Company Information Table 81. Zoetis Business Overview Table 82. Zoetis Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Zoetis Prophylactic Human Vaccine Product Portfolio Table 84. Zoetis Recent Development Table 85. Merial Company Information Table 86. Merial Business Overview Table 87. Merial Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Merial Prophylactic Human Vaccine Product Portfolio Table 89. Merial Recent Development Table 90. McKesson Medical Company Information Table 91. McKesson Medical Business Overview Table 92. McKesson Medical Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. McKesson Medical Prophylactic Human Vaccine Product Portfolio Table 94. McKesson Medical Recent Development Table 95. Biovac Company Information Table 96. Biovac Business Overview Table 97. Biovac Prophylactic Human Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Biovac Prophylactic Human Vaccine Product Portfolio Table 99. Biovac Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Prophylactic Human Vaccine Distributors List Table 103. Prophylactic Human Vaccine Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Prophylactic Human Vaccine Product Image Figure 2. Global Prophylactic Human Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prophylactic Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Prophylactic Human Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Prophylactic Human Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Prophylactic Human Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Inactivated Vaccine Image Figure 10. Attenuated Vaccine Image Figure 11. Others Image Figure 12. Global Prophylactic Human Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Prophylactic Human Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Prophylactic Human Vaccine Sales Volume Share by Type (2021-2032) Figure 15. Global Prophylactic Human Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Prophylactic Human Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Prophylactic Human Vaccine Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Scientific Research Image Figure 20. Others Image Figure 21. Global Prophylactic Human Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Prophylactic Human Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Prophylactic Human Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Prophylactic Human Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Prophylactic Human Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Prophylactic Human Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Prophylactic Human Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Prophylactic Human Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Prophylactic Human Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Prophylactic Human Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Prophylactic Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Prophylactic Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Prophylactic Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Prophylactic Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Prophylactic Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Prophylactic Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Prophylactic Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Prophylactic Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Prophylactic Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Prophylactic Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Prophylactic Human Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Prophylactic Human Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated Vaccine
  • Attenuated Vaccine
  • Others
Applications
  • Hospital
  • Scientific Research
  • Others
Companies covered
  • GSK
  • Sanofi
  • Merck
  • Zoetis
  • Merial
  • McKesson Medical
  • Biovac

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Prophylactic Human Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Prophylactic Human Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Prophylactic Human Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Prophylactic Human Vaccine Market Dynamics
  1. 2.1 Prophylactic Human Vaccine Industry Trends
  2. 2.2 Prophylactic Human Vaccine Industry Drivers
  3. 2.3 Prophylactic Human Vaccine Industry Opportunities and Challenges
  4. 2.4 Prophylactic Human Vaccine Industry Restraints
3 Prophylactic Human Vaccine Market by Company
  1. 3.1 Global Prophylactic Human Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Prophylactic Human Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Prophylactic Human Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Prophylactic Human Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Prophylactic Human Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Prophylactic Human Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Prophylactic Human Vaccine Company Product Type and Application
  8. 3.8 Global Prophylactic Human Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Prophylactic Human Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Prophylactic Human Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Prophylactic Human Vaccine Market by Type
  1. 4.1 Prophylactic Human Vaccine Type Introduction
  2. 4.1.1 Inactivated Vaccine
  3. 4.1.2 Attenuated Vaccine
  4. 4.1.3 Others
  5. 4.2 Global Prophylactic Human Vaccine Sales Volume by Type
  6. 4.2.1 Global Prophylactic Human Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Prophylactic Human Vaccine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Prophylactic Human Vaccine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Prophylactic Human Vaccine Sales Value by Type
  10. 4.3.1 Global Prophylactic Human Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Prophylactic Human Vaccine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Prophylactic Human Vaccine Sales Value Share by Type (2021-2032)
5 Prophylactic Human Vaccine Market by Application
  1. 5.1 Prophylactic Human Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Scientific Research
  4. 5.1.3 Others
  5. 5.2 Global Prophylactic Human Vaccine Sales Volume by Application
  6. 5.2.1 Global Prophylactic Human Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Prophylactic Human Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Prophylactic Human Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Prophylactic Human Vaccine Sales Value by Application
  10. 5.3.1 Global Prophylactic Human Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Prophylactic Human Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Prophylactic Human Vaccine Sales Value Share by Application (2021-2032)
6 Prophylactic Human Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Prophylactic Human Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prophylactic Human Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Prophylactic Human Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Prophylactic Human Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Prophylactic Human Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Prophylactic Human Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Prophylactic Human Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Prophylactic Human Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Prophylactic Human Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Prophylactic Human Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Prophylactic Human Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Prophylactic Human Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Prophylactic Human Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Prophylactic Human Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Prophylactic Human Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Prophylactic Human Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Prophylactic Human Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Prophylactic Human Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Prophylactic Human Vaccine Sales Value Share by Country, 2025 VS 2032
7 Prophylactic Human Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Prophylactic Human Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Prophylactic Human Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Prophylactic Human Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Prophylactic Human Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Prophylactic Human Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Prophylactic Human Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Prophylactic Human Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Prophylactic Human Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Prophylactic Human Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Prophylactic Human Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Prophylactic Human Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Prophylactic Human Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Prophylactic Human Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Prophylactic Human Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Prophylactic Human Vaccine Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Prophylactic Human Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Prophylactic Human Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Zoetis
  20. 8.4.1 Zoetis Company Information
  21. 8.4.2 Zoetis Business Overview
  22. 8.4.3 Zoetis Prophylactic Human Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zoetis Prophylactic Human Vaccine Product Portfolio
  24. 8.4.5 Zoetis Recent Developments
  25. 8.5 Merial
  26. 8.5.1 Merial Company Information
  27. 8.5.2 Merial Business Overview
  28. 8.5.3 Merial Prophylactic Human Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merial Prophylactic Human Vaccine Product Portfolio
  30. 8.5.5 Merial Recent Developments
  31. 8.6 McKesson Medical
  32. 8.6.1 McKesson Medical Company Information
  33. 8.6.2 McKesson Medical Business Overview
  34. 8.6.3 McKesson Medical Prophylactic Human Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 McKesson Medical Prophylactic Human Vaccine Product Portfolio
  36. 8.6.5 McKesson Medical Recent Developments
  37. 8.7 Biovac
  38. 8.7.1 Biovac Company Information
  39. 8.7.2 Biovac Business Overview
  40. 8.7.3 Biovac Prophylactic Human Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biovac Prophylactic Human Vaccine Product Portfolio
  42. 8.7.5 Biovac Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Prophylactic Human Vaccine Value Chain Analysis
  2. 9.1.1 Prophylactic Human Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Prophylactic Human Vaccine Sales Mode & Process
  6. 9.2 Prophylactic Human Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Prophylactic Human Vaccine Distributors
  9. 9.2.3 Prophylactic Human Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst